Gottsegen National Cardiovascular Center
Budapest, Hungary
5 recruiting
Showing 1–5 of 5 trials
Recruiting
Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1153 locationsNCT07064473
Recruiting
Phase 3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Heart Failure
Boehringer Ingelheim4,200 enrolled641 locationsNCT06935370
Recruiting
Phase 3
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Heart Failure
Boehringer Ingelheim6,000 enrolled652 locationsNCT06424288
Recruiting
The Role of a Structured Patient Education Programme in the Complex Care of Patients With Heart Failure
Heart Failure
Gottsegen National Cardiovascular Institute1,000 enrolled1 locationNCT07451457
Recruiting
Phase 3
Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH
Pulmonary Arterial Hypertension
AOP Orphan Pharmaceuticals AG20 enrolled5 locationsNCT06350032